Gastrointestinal cancer refers to malignant conditions of the gastrointestinal tract, including the esophagus, stomach, liver, biliary system, pancreas, bowels, and anus.
Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer.
Aptium Oncology, Inc. today announced the launch of Aptium Oncology Myeloma Consortium (AMyC), a broad-based collaboration that brings together renowned investigators to work with pharmaceutical sponsors to advance clinical and translational research in myeloma and related cancers.
Researchers from The University of Texas M. D. Anderson Cancer Center have developed a new assessment tool to measure the severity of symptoms that can complicate stem cell transplantation. The tool assesses symptoms resulting from chronic graft-versus-host disease (cGVHD), and was presented with supporting research at the 2010 Bone and Marrow Transplant Tandem Meeting.
The Georgetown Lombardi Comprehensive Cancer Center hosts a symposium exploring the future of cancer research on Feb. 17th at Georgetown University Medical Center. Sponsored by the Ruesch Center for the Cure of Gastrointestinal Cancers, the two-part symposium, "Fighting a Smarter War Against Cancer: Personalized Medicine & the Cure for Cancer," will offer a focus on personalized medicine by bringing together experts in academia, industry and advocacy.
GenVec, Inc. announced today that data from the Company's trial in esophageal cancer were presented at the American Society of Clinical Oncology's 2010 Gastrointestinal Cancer Symposium in Orlando, Florida on January 22, 2010.
The glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null genotypes have been linked to increased risk of developing cancer. The results regarding the association between GSTM1 and GSTT1 null genotypes and the risk of GC or CRC were contradictory.
Scientists have begun a three-year study to analyse why cancer patients become resistant to treatments designed to fight the disease. A research team from Kingston University has been awarded £99,000 to investigate why some tumours are sensitive and respond to treatments and why other tumours do not.
There are minimal data assessing the relationship between diabetes with gallbladder, biliary and pancreatic cancer. Recent small studies have suggested an elevated risk of pancreatic cancer only in patients with diabetes mellitus (DM).
New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans.
Georgetown University Medical Center today announced the creation of a center that may help advance a cure for one of the deadliest forms of cancer. The Otto J. Ruesch Center for the Cure of Gastrointestinal (GI) Cancers will fund gastrointestinal cancer research, drug discovery and patient advocacy efforts at the Georgetown Lombardi Comprehensive Cancer Center.
Cases of primary liver cancer have tripled in the last 30 years according to statistics published today by Cancer Research UK.
A Michigan State University researcher is challenging health standards that consider nitrates and nitrites in food to be harmful.
When a cancer patient and his or her doctor discuss the value of a treatment option, the conversation usually centers on a consideration of the treatment's medical benefits versus its possible side effects for the patient. Increasingly, however, as the already high costs of cancer care continue to rise, a full view of the patient's welfare must also take into account the economic impact of the treatment on the patient and his or her family.
Human immune cells communicate constantly with one another as they coordinate to fight off infection and other threats.
Interim results from a nationwide clinical trial led by a University of North Carolina at Chapel Hill researcher suggest that radiofrequency ablation is an effective treatment for dysplasia in people with Barrett's esophagus, a condition that can lead to deadly gastrointestinal cancer.
Italian scientists say the benefits of some cancer drugs may be exaggerated as a rising number of trials are stopped early.
A study by researchers at the John Wayne Cancer Institute at Saint John's Health Center has shown that a receptor protein found on melanoma cells appears to facilitate the disease's spread to the small intestine.
The latest research says that by eating just three servings a month of raw broccoli or cabbage a person can reduce their risk of bladder cancer by as much as 40 percent.
Using a new bottom-up approach for rational drug design, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have reengineered the powerful anticancer drug imatinib - best known by its brand name Gleevec - to more specifically target one type of cancer while potentially curbing a rare life-threatening cardiotoxic side effect.
Counting circulating tumor cells before and after the start of treatment for patients with metastatic colorectal cancer could help doctors determine when or if a change in treatment should be made.